新闻
Pharmaceutical Fronts | 2021第一期全新上线 2021-07-05

封面.jpg

603f023d2ee4c.png

Issue 01 · Volume 03 · March 2021

6063cfa70469c.png


Discovery of SIPI6473, a New, Potent, and Orally Bioavailable Multikinase Inhibitor for the Treatment of Non-small Cell Lung Cancer

Gu, Xiu; Zhang, Zi-Xue; Jiao, Min-Ru; Peng, Xin-Yan; Li, Jian-Qi; Zhang, Qing-Wei

60e26d01946e2.jpg

According to the binding model of Erlotinib with EGFR protein, compound B5 (also named SIPI6473) was designed by conformational restriction. B5 inhibited the activity of several kinases (such as EGFR, VEGFR2, and PDGFRα) that contributed to NSCLC development. In vivo study also showed that B5 inhibited tumor growth without signs of adverse effects in the A549 xenograft model. B5 may represent a new and promising drug for the treatment of NSCLC. EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer.

Phenolic Constituents from the Stems of Morus nigra and their α-Glucosidase Inhibitory Activities

Wang, Ling-Ling; Xu, Liang-Jin; Ma, Meng-Jie; Huang, Chun-Yue; Wu, Tong; Hu, Xiao

60e26cf9b3ee8.jpg

A new sanggenon-type flavanone, nigragenon F (1), together with 11 known compounds, were isolated from the stems of Morus nigra. α-glucosidase inhibitory effect test provided different structure-type α-glucosidase inhibitors from M. nigra, not only enriching the library of natural α-glucosidase inhibitors, but also laying experimental basis for the development and utilization of M. nigra as hypoglycemic medicinal plant resources.

Synthesis and Antitumor Activity of (3-Hydroxyacrylato-O,O′) Diammineplatinum(II)

Shu, Yong-Zhi; Lin, Jun; Zhu, Bao-Quan; Liu, Quan-Hai; Zhou, Bin; Hu, Hai-Feng; Ju, Dian-Wen

60e26cef72c05.jpg

This paper firstly synthetized two platinum(II) complexes with Michael acceptor 3-hydroxyacrylic acid as the leaving group. Results from MTT assay showed that the anticancer effects of complexes 1 and 2 were similar to that of oxaliplatin in two human cancer cell lines (HCT-116 and A549). An in vivo study showed that administration of complexes 1 at a higher dose and a longer interval may serve as promising drug candidates in cancer therapy.

Synthesis of Natural Product-Like Tricyclic Higher-Carbon Sugar Nucleosides

Yuan, Xiao-Han; Wang, Shuai; Wang, Xiao-Ning; Yu, Bin; Liu, Hong-Min

60e26ce2c9320.jpg

A series of structurally novel bis-uracil containing tricyclic higher-carbon sugar nucleosides (4a-e) were firstly synthesized using D-xylose as the starting material and the classical Vorbruggen glycosylation as the key synthetic step. The synthetic routes are straightforward, high-yielding, and could be utilized for accessing more analogs for biological screens.

Synthesis of a Novel PTH1–34 Analog with Increased Human Serum Albumin Affinity

Ruan, Si-Da; Dong, Yuan-Zhen; Lu, Jian-Guang; Zhao, Meng-Jia; Lu, Wei-Gen; Feng, Jun

60e26cd318317.jpg

This approach provides a novel PTH1-34 analog, PTH-Lys27-AGC, which may be along-acting agent for osteoporosis treatment in the future.

The Expression of Recombinant Human Serum Albumin in the Mammary Gland of Transgenic Mice

Gong, Gui-Hua; Han, Shu; Huang, Xiao-Ling; Xie, Li-Ping; Zhang, Wei; Xu, Lei; Hu, You-Jia

60e26cca9ed5d.jpg

In this study, an HSA minigene, containing the cDNA of HSA and an intron 1, was firstly constructed. A 2 chickenglobin insulator was added upstream of the promoter as a transcriptionenhancer, while a 7.9 kb αs1-casein 3′ flank sequence was used to strengthen the transcription termination located at the downstream of the expression cassette. The strategy of rHSA expression construct provides an alternative of successful expressions of rHSA, and probably other RPs, in the mammary glands of transgenic mice. HSA, human serum albumin, rHSA, recombinant HAS, RPs, recombinant proteins.

Pharmaceutical Fronts

期刊宗旨 反映全球医药工业及其相关领域的工业化、工程化、产业化研究的重大成果为目标,报道医药工业领域前沿研究内容,兼及新技术、新设备和新方法的介绍与推广。涵盖医药工业研发流程上下游相关内容,重点突出实用及新型技术。

栏目设置 原创研究论文,高质量的综述,评论和简讯

研究领域 化学药物与合成技术/不对称催化与绿色化学/药物化学/微生物药物和生物制药/药物科学与制剂技术/分析科学/工程创新/工艺安全与法规科学

主办单位 中国医药工业研究总院

协办单位 中国医药工业信息中心

主编 陈芬儿(中国工程院院士、复旦大学教授)

6093c1412775f.jpg

Pharmaceutical Fronts已经被DOAJ收录!

欢迎有关制药领域所有相关主题的原创研究论文、高质量的综述、评论和简讯,包括:

  • 化学药物与合成技术(Drug & Synthesis Technology)

  • 不对称催化与绿色化学(Asymmetric Catalysis and Green Chemistry)

  • 药物化学(Medicinal Chemistry)

  • 微生物药物和生物制药(Biopharmaceuticals)

  • 药物科学与制剂技术(Pharmaceutical Sciences and Formulation Technology)

  • 分析科学(Analytical Sciences)

  • 工程创新(Engineering Innovations)

  • 工艺安全与法规科学(Process Safety and Regulatory Sciences)


投稿及支持请联系:

E  Zhangll_ea_pharm@126.com

T  +86-021-6289 7080